Events

New data for the immunotherapy DARZALEX (daratumumab) and first-in-class BTK inhibitor IMBRUVICA (ibrutinib) are among eight oral presentations from Janssen Research & Development, LLC, to be featured at the 59th American Society of Hematology Annual Meeting & Exhibition taking place December 9-12, in Atlanta, GA.
Proceeds from the 100-meter race on Nov. 4 will be donated to Parent Project Muscular Dystrophy (PPMD), the largest U.S. nonprofit organization focused on ending Duchenne muscular dystrophy.
PRESS RELEASES